Latest AILatest AI

$

AI Steps Into a Key Bottleneck in Drug Discovery


By: Latest AI Team

Apr 27, 2026 - 09:12 AM
272

2 min read


AI Steps Into a Key Bottleneck in Drug Discovery

Single-cell omics is now widely used in drug discovery, from early target work to biomarkers and translational studies. It lets researchers study biology at the level of individual cells. But more data has not made interpretation easier.

As Parashar Dhapola puts it, “going from that massive single-cell raw data to something that’s actionable is very, very slow.”

Why annotation is the real challenge

After clustering cells, the next step is annotation. This is where clusters are given biological meaning. A label like T cell or macrophage is often not enough. What matters is functional state, such as active vs exhausted cells.

If annotation lacks depth, the entire analysis can fall apart. Dhapola warns that “that can be catastrophic” because it links statistics to biology.

Where things slow down

Tools like Scanpy and Seurat already handle preprocessing well. The real bottleneck comes later.

Researchers go back and forth refining clusters, testing markers, and debating meaning. This iterative loop takes time and often delays decisions.

Why AI fits here

AI has worked well in structured pharma tasks like documents and imaging. Biology is harder. It is open-ended.

Single-cell annotation sits in between. It needs both structure and judgment. That makes it a practical but tricky target for AI.

Nygen’s approach to fixing it

Nygen Analytics focuses only on annotation. Its platform CyteType sits on top of existing pipelines and adds an interpretation layer.

Instead of one model, it uses multiple controlled agents. These combine gene markers, literature, and context into structured outputs.

Transparency is key. The system shows how decisions are made, reducing risks like hallucination or cherry-picking data.

Why this matters

Better annotation reveals hidden signals. It can uncover disease-linked cell states or treatment responses that broad labels miss.

Nygen’s goal is simple. Not to replace experts, but to make interpretation faster, clearer, and more reproducible.

✧ The End ✧

Keywords
AIDrug Discovery
Related News